ClinicalTrials.gg
TerminatedNCT03633526Updated Feb 5, 2020Results posted

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

A Phase 3 interventional study of VX-659/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 6 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Why this study was terminated
Study discontinued after Part A due to Sponsor's discretion.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
74th of 84
18 · median 70
Started
2018
with 7 others
Phase 3
45 of 84
none open now
Registered
57th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 74th largest by enrollment, is one of 8 that started in 2018, is one of 45 in phase 3, and was the 57th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-659, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects with F/F or F/MF genotypes.

The study was discontinued after completion of Part A due to Sponsor's discretion.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Homozygous or heterozygous for F508del mutation (F/F or F/MF genotypes)
  • (FEV1) value ≥40% of predicted mean for age, sex, and height.

Key Exclusion Criteria:

  • cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status.
  • Solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    VX-659/TEZ/IVA

    Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.

    Drug: VX-659/TEZ/IVA · Drug: IVA

Interventions

  • DrugVX-659/TEZ/IVA

    VX-659/TEZ/IVA FDC tablet.

    Also known as: VX-659/VX-661/VX-770, VX-659/tezacaftor/ivacaftor

  • DrugIVA

    IVA mono tablet.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of VX-659, TEZ, and IVA

    Time frame: Day 1 and Day 15

  2. Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, and IVA

    Time frame: Day 8 and Day 15

  3. Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of VX-659, TEZ, and IVA

    Time frame: Day 1 and Day 15

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)

    Time frame: Day 1 and Day 15

  2. Observed Pre-Dose Concentration (Ctrough) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)

    Time frame: Day 8 and Day 15

  3. Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)

    Time frame: Day 1 and Day 15

  4. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 6 weeks)

07

Results

Posted Feb 5, 2020
Limitations and caveats
The study was terminated before start of Part B due to sponsor discretion.

Participant flow

A total of 18 participants were enrolled in this study. Two participants were enrolled but were not dosed in triple combination (TC) treatment period. Therefore, results are reported for 16 participants.

Participant flow — Overall Study
MilestoneVX-659/TEZ/IVA
Started16
Completed16
Not completed0

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of VX-659, TEZ, and IVA
Time frame:
Day 1 and Day 15
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Concentration (Cmax) of VX-659, TEZ, and IVA
microgram per milliliter (mcg/mL)VX-659/TEZ/IVA
VX-659: Day 11.81 ± 0.858
VX-659: Day 152.55 ± 1.21
TEZ: Day 14.53 ± 1.65
TEZ: Day 155.22 ± 1.69
IVA: Day 10.536 ± 0.208
IVA: Day 150.733 ± 0.256
PrimaryObserved Pre-Dose Concentration (Ctrough) of VX-659, TEZ, and IVA
Time frame:
Day 8 and Day 15
Reported as:
Mean · mcg/mL
Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, and IVA
mcg/mLVX-659/TEZ/IVA
VX-659: Day 80.358 ± 0.259
VX-659: Day 150.367 ± 0.283
TEZ: Day 80.897 ± 0.488
TEZ: Day 150.740 ± 0.421
IVA: Day 80.289 ± 0.195
IVA: Day 150.283 ± 0.241
PrimaryArea Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of VX-659, TEZ, and IVA
Time frame:
Day 1 and Day 15
Reported as:
Mean · hour*mcg/mL (h*mcg/mL)
Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of VX-659, TEZ, and IVA
hour*mcg/mL (h*mcg/mL)VX-659/TEZ/IVA
VX-659: Day 15.41 ± 3.65
VX-659: Day 158.55 ± 4.50
TEZ: Day 115.5 ± 5.36
TEZ: Day 1519.3 ± 7.26
IVA: Day 11.64 ± 0.795
IVA: Day 152.95 ± 1.18
SecondaryMaximum Observed Concentration (Cmax) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame:
Day 1 and Day 15
Reported as:
Mean · mcg/mL
Maximum Observed Concentration (Cmax) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
mcg/mLVX-659/TEZ/IVA
M1-TEZ: Day 11.63 ± 0.553
M1-TEZ: Day 155.04 ± 1.27
M1-IVA: Day 11.25 ± 0.449
M1-IVA: Day 151.73 ± 0.741
SecondaryObserved Pre-Dose Concentration (Ctrough) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame:
Day 8 and Day 15
Reported as:
Mean · mcg/mL
Observed Pre-Dose Concentration (Ctrough) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
mcg/mLVX-659/TEZ/IVA
M1-TEZ: Day 83.56 ± 1.33
M1-TEZ: Day 153.35 ± 1.23
M1-IVA: Day 80.816 ± 0.491
M1-IVA: Day 150.858 ± 0.672
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame:
Day 1 and Day 15
Reported as:
Mean · h*mcg/mL
Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
h*mcg/mLVX-659/TEZ/IVA
M1-TEZ: Day 15.52 ± 2.87
M1-TEZ: Day 1525.2 ± 7.70
M1-IVA: Day 13.60 ± 1.87
M1-IVA: Day 156.98 ± 2.94
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsVX-659/TEZ/IVA
Participants with AEs13
Participants with SAEs1

Adverse events

Collected over From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 6 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VX-659/TEZ/IVA0/16 (0%)1/16 (6.3%)13/16 (81.3%)
Most frequent serious events
Most frequent serious events
EventVX-659/TEZ/IVA
RashSkin and subcutaneous tissue disorders1/16
Most frequent other events
Showing 10 of 30
Most frequent other events
EventVX-659/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders7/16
HeadacheNervous system disorders6/16
FatigueGeneral disorders3/16
VomitingGastrointestinal disorders2/16
PyrexiaGeneral disorders2/16
Productive coughRespiratory, thoracic and mediastinal disorders2/16
Sputum increasedRespiratory, thoracic and mediastinal disorders2/16
Abdominal discomfortGastrointestinal disorders1/16
Post-tussive vomitingGastrointestinal disorders1/16
ChillsGeneral disorders1/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)VX-659/TEZ/IVA
Mean9.2 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)VX-659/TEZ/IVA
Female5
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VX-659/TEZ/IVA
Hispanic or Latino2
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VX-659/TEZ/IVA
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White16
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Clinical Research of Charlotte
    Charlotte, North Carolina 28277, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jan 2019, 5 months.

Results were first posted in Feb 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2018
First posted
Aug 16, 2018
StartActual
Aug 3, 2018
Primary completionActual
Jan 18, 2019
CompletionActual
Jan 18, 2019
Results first posted
Feb 5, 2020
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03633526
Responsible party
Sponsor
First posted
Aug 16, 2018
Start date
Aug 3, 2018
Primary completion
Jan 18, 2019
Completion
Jan 18, 2019
Results posted
Feb 5, 2020
Last update
Feb 5, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion